1.	Phase I/II Study of Vaccination With Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding For Melan-A, MAGE-3, and Survivin Antigens in Patients With Stage IV Cutaneous Melanoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ERLANGEN-DERMA-ER-DC-06, EU-20317, NCT00074230
2.	Phase II Randomized Study of Multipeptide Vaccination Comprising Recombinant MAGE-3.1 Antigen, MART-1 Antigen, gp100 Antigen, and NA17-A2 Peptide Vaccines Emulsified With Montanide ISA-51 With Versus Without Recombinant Interleukin-12 Followed by Daclizumab in Patients With Metastatic Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-10-324-B, 10-324-B, 8445, NCT01307618
3.	Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120045, 12-C-0045, NCT01495572
4.	Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells Phase: Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: Pro00000806, IND # BB-13545, NIH OBA # 0708-874, NCT00672542